MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026)

MoonLake Immunotherapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation changed N/A year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $13.4 million (up 1290.29% YoY), while the FY2024 annual figure was $555000.0, down 92.19% from the prior year.
• Share-based Compensation for Q1 2026 stood at $13.4 million, up from -$4.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $13.4 million in Q1 2026, with the low at -$4.8 million in Q4 2024.
• The 4-year median for Share-based Compensation is $2.0 million (2022), against an average of $2.4 million.
• Peak annual rise in Share-based Compensation reached 249.17% in 2024, while the deepest fall reached 398.54% in 2024.
• MoonLake Immunotherapeutics' Share-based Compensation stood at $2.6 million in 2022, then slumped by 38.17% to $1.6 million in 2023, then plunged by 398.54% to -$4.8 million in 2024, then jumped by 378.64% to $13.4 million in 2026.
• Business Quant data shows MLTX's Share-based Compensation at $13.4 million in Q1 2026, -$4.8 million in Q4 2024, and $5.0 million in Q3 2024.